摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-Amino-2,4-dioxo-5-(4-phenylmethoxyphenyl)-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile

中文名称
——
中文别名
——
英文名称
7-Amino-2,4-dioxo-5-(4-phenylmethoxyphenyl)-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
——
7-Amino-2,4-dioxo-5-(4-phenylmethoxyphenyl)-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
——
化学式
C21H16N4O4
mdl
——
分子量
388.382
InChiKey
WARSUIGSNFZTHC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    127
  • 氢给体数:
    3
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    巴比妥酸4-苄氧基苯甲醛丙二腈 在 triphenyl(propyl-3-hydrogensulfate)phosphonium bromide 作用下, 以 乙醇 为溶剂, 反应 0.58h, 以92%的产率得到7-Amino-2,4-dioxo-5-(4-phenylmethoxyphenyl)-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    三苯基(丙基-3-硫酸氢))溴化物的合成及新型高效离子液体催化剂的合成5-亚芳基巴比妥酸和吡喃并[2,3-d]嘧啶衍生物
    摘要:
    我们报告了作为可重复使用的绿色布朗斯台德酸性离子液体催化剂的三苯基(丙基-3-硫酸氢)溴化phosph([TPPHSP] Br)的合成及其在5-亚芳基巴比妥酸和吡喃并[2,3- d]合成中的应用芳香醛与巴比妥酸或芳香醛,丙二腈和巴比妥酸在EtOH-H 2 O中回流条件下的缩合反应,可产生良好的收率。[TPPHSP] Br IL催化剂通过傅里叶变换红外光谱(FT-IR),1 H和13 C核磁共振(NMR)和热重分析(TG)进行表征,显示出良好的催化活性和可重复使用性。
    DOI:
    10.1007/s11164-019-03798-0
点击查看最新优质反应信息

文献信息

  • Nano-Zn[2-boromophenylsalicylaldiminemethylpyranopyrazole]Cl<sub>2</sub>as a novel nanostructured Schiff base complex and catalyst for the synthesis of pyrano[2,3-<i>d</i>]pyrimidinedione derivatives
    作者:A.R. Moosavi-Zare、H. Goudarziafshar、Z. Jalilian
    DOI:10.1002/aoc.4584
    日期:2019.1
    several techniques. Nano‐[Zn‐2BSMP]Cl2 was used as an effective catalyst for the preparation of some pyrano[2,3‐d]pyrimidinedione derivatives by the multicomponent reaction of malononitrile, aryl aldehydes and barbituric acid derivatives. The novelty and efficiency of nano‐[Zn‐2BSMP]Cl2 as a catalyst, in comparison with some other reported catalysts, for this synthetic transformation are the main features
    制备了一种新型的纳米结构的席夫碱复合物纳米Zn [2-苯基苯基水杨醛亚胺基甲基喃并吡唑] Cl 2(nano [Zn-2BSMP] Cl 2),并使用多种技术对其进行了表征。纳米[Zn-2BSMP] Cl 2被用作通过丙二腈,芳基醛和巴比妥酸生物的多组分反应制备某些喃并[2,3- d ]嘧啶二酮衍生物的有效催化剂。与其他报道的催化剂相比,纳米[Zn-2BSMP] Cl 2作为催化剂的新颖性和效率是这项工作的主要特征。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione